Jun 23, 2025 08:30AM
Jun 17, 2025 02:57PM
Jun 17, 2025 02:55PM
May 19, 2025 05:34PM
May 19, 2025 05:30PM
Mar 20, 2025 07:00AM
Feb 6, 2025 06:43AM H.C. Wainwright Reiterates Neutral Rating on Eyenovia (EYEN)
Nov 12, 2024 04:05PM
Oct 16, 2024 07:00AM
Oct 1, 2024 07:03AM
Oct 1, 2024 07:00AM
Sep 27, 2024 08:31AM
Sep 27, 2024 08:30AM
Sep 26, 2024 07:01AM Eyenovia (EYEN) Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery
Sep 26, 2024 07:00AM
Sep 9, 2024 03:00AM
Sep 5, 2024 07:00AM
Sep 3, 2024 07:02AM
Sep 3, 2024 07:00AM
Aug 13, 2024 07:00AM
Aug 12, 2024 04:05PM Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Aug 8, 2024 07:00AM
Aug 7, 2024 05:11PM
Aug 7, 2024 08:00AM
Jul 30, 2024 08:00AM
Jul 30, 2024 08:00AM
Jul 30, 2024 08:00AM
Jul 23, 2024 07:01AM Eyenovia Inc (EYEN) and Senju Pharmaceutical Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye Disease
Jul 23, 2024 07:00AM
Jul 1, 2024 06:50AM
Jul 1, 2024 06:50AM
May 15, 2024 04:01PM
May 14, 2024 07:00AM
Apr 25, 2024 07:01AM
Apr 25, 2024 07:00AM Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension
Apr 8, 2024 07:02AM
Apr 8, 2024 07:00AM
Mar 18, 2024 04:05PM
Mar 13, 2024 07:04AM
Mar 13, 2024 07:00AM
Mar 11, 2024 07:00AM
Mar 5, 2024 08:00AM Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery
Mar 4, 2024 05:55PM
Feb 13, 2024 07:00AM
Feb 13, 2024 07:00AM
Jan 16, 2024 07:03AM
Jan 16, 2024 07:00AM
Nov 13, 2023 04:05PM
Nov 6, 2023 08:00AM Eyenovia to Report Third Quarter 2023 Results on Monday, November 13
Nov 2, 2023 07:04AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All